The Asia Pacific Vaccines Market was valued at $2002.2 Million in 2025 and projected to reach to $2850.6 Million by 2030, representing a compound annual growth rate of 7.3%. The Asia Pacific rotavirus vaccine market is poised for sustained growth through 2030, driven by increasing government healthcare spending, rising awareness of rotavirus-related pediatric diseases, and strengthened immunization infrastructure across developing economies.
Asia Pacific's rotavirus vaccine market is experiencing robust growth at 7.3% CAGR, driven by expanding immunization programs across China, India, and Japan, with market size projected to reach $2,850.6 million by 2030.
China dominates the Asia Pacific rotavirus vaccine segment with a market size of $1,278.9 million, reflecting strong government vaccination initiatives and increasing pediatric healthcare investments across urban and rural regions.
India's rotavirus vaccine market valued at $728.7 million represents significant untapped potential, supported by rising awareness of gastroenteritis prevention and expanding public health immunization programs targeting underserved populations.
Japan's $764.9 million rotavirus vaccine market reflects advanced healthcare infrastructure and high vaccination adoption rates, positioning it as a key revenue driver alongside established immunization protocols.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | PNEUMOCOCCAL DISEASE (Disease Indication) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 7.3% from 2025 to 2030 |
| Largest Segment | INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (Route Of Administration) |
| Market Size Base Year (Billions) | ~USD 47.75 (2025) |
| Revenue Forecast (Billions) | ~USD 67.91 (2030) |
| Segments Covered | Disease Indication, Technology, Type, Route Of Administration, End User |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Engineered automated manufacturing and assembly systems,Pre- and post-automation services,Contract manufacturing and integration services, |
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs approximately 7,000 people. The company specializes in automation and tooling systems for industrial applications.
| Country | 2025 size (native) |
|---|---|
| China | USD 1278.9 Million |
| India | USD 728.7 Million |
| Japan | USD 764.9 Million |
| South Korea | USD 234.4 Million |
| Rest Of Asia Pacific | USD 1244.6 Million |
The Rotavirus vaccine market was valued at $2,002.2 million in 2025 and is projected to reach $2,850.6 million by 2030.
Rotavirus vaccines are expected to grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2030.
Rotavirus market growth is driven by both developed markets with mature immunization programs and emerging markets with increasing adoption and government-backed vaccination initiatives.
Rotavirus vaccine demand is supported by clinical efficacy data, integration into national immunization schedules, government health programs, and rising awareness of rotavirus gastroenteritis prevention.
Multiple Rotavirus vaccine formulations are available globally, with different manufacturers offering oral rotavirus vaccines approved for pediatric immunization programs.
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global vaccines market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the vaccines market. The secondary sources used for this study include World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC), the Global Cancer Observatory (GLOBOCAN), the National Institutes of Health (NIH), Center of Disease Control & Prevention (CDC), US Department of Health and Human Services, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), World Cancer Research Fund International (WCRF International), European Medicines Agency (EMA), The National Medical Products Administration (NMPA), Global Alliance for Vaccines and Immunization (GAVI), United States Food & Drug Administration (US FDA), Orange book, Purple book, Clinical trials.gov, Pan American Health Organization (PAHO), United Nation International Children’s Emergency Fund (UNICEF), Department of health and Human Services (HHS), and International Society for Vaccines (ISV). Corporate filings include annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global vaccines market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were employed to estimate and validate the overall size of the vaccines market. These methods were also widely used to determine the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After estimating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown techniques were used where applicable to finalize the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both demand and supply sides.
A vaccine is a biologically formulated product designed to trigger active acquired immunity against a specific infectious or malignant disease. Vaccines work by stimulating the immune system to identify and fight harmful agents, such as viruses or bacteria. They generally consist of parts that resemble the disease-causing microorganism, often in weakened or deactivated forms, along with their toxins or surface proteins. The report solely focuses on human vaccines and does not include veterinary vaccines, which are outside the scope of this study.
Full forecast, segment splits, and company analysis for all Vaccines Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report